Stock 605507 GUOBANG PHARMA LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Guobang Pharma Ltd.

Equities

605507

CNE100004NS2

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-07-08 pm EDT 		5-day change 1st Jan Change
16.4 CNY +2.37% Intraday chart for Guobang Pharma Ltd. -1.15% -6.61%
Apr. 15 Guobang Pharma Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Jan. 27 Guobang Pharma Ltd. announces an Equity Buyback for CNY 200 million worth of its shares. CI

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

  • The company returns high margins, thereby supporting business profitability.
  • With a P/E ratio at 12.71 for the current year and 8.16 for next year, earnings multiples are highly attractive compared with competitors.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
GUOBANG PHARMA LTD. Stock Guobang Pharma Ltd.
-6.61% 1.25B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+59.97% 840B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+38.28% 621B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.18% 354B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.61% 319B
B-
ABBVIE INC. Stock AbbVie Inc.
+8.44% 297B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.64% 237B
B+
NOVARTIS AG Stock Novartis AG
+14.73% 221B
B-
ROCHE HOLDING AG Stock Roche Holding AG
+0.61% 220B
A+
AMGEN INC. Stock Amgen Inc.
+9.68% 169B
C+
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 605507 Stock
  4. Ratings Guobang Pharma Ltd.